After robust Q3 figures.
Profit greatly beats expectations.
Regardless of rouble trouble.
Pharma firm buys treasury shares again for HUF 370 mn.
Signs exclusive distribution agreement with Prima-Temp.
For the commercialisation of novel drug in Europe, Latin America and other markets.
Erik Bogsch will remain Chairman of the Board, though.
As of 1 August.
Despite profit plunge.
Earnings report to be published this week.
Marketing of key drug green-lighted for Western Europe.
Key drug to hit shelves in Western Europe soon.
Nearly 20 billion forints worth of dividend will be paid.
Operating profit margin also seen higher.
Leading pharma reports robust Q1 results.
The rating is 'Overweight'.
Annual General Meeting to be held on 26 April.
There are only a handful of women in senior roles.
Magyar Telekom and OTP are the top picks.
'Buy' rating remains.